Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Rowe

Showing results (401-410 of 504) with videos related to

Pageof 51
Sort By:
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
Radiology|July 19, 2022
<sup>18</sup>F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic ConfirmationGary A Ulaner, Beth Thomsen, Jeffrey Bassett, et al.
European Urology Focus|March 3, 2020
Cost-effectiveness Analysis of <sup>99m</sup>Tc-sestamibi SPECT/CT to Guide Management of Small Renal MassesZhuo T Su, Hiten D Patel, Mitchell M Huang, et al.
The Prostate|May 11, 2023
Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapyXinxing Du, Yanhao Dong, Jiazhou Liu, et al.
European Urology|September 21, 2015
Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe TumorsMichael A Gorin, Steven P Rowe, Alexander S Baras, et al.
Clinical Nuclear Medicine|March 22, 2023
Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and TherapyPhilipp E Hartrampf, Aleksander Kosmala, Sebastian E Serfling, et al.
The Prostate|July 31, 2019
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancerChanning J Paller, Danilo Piana, James R Eshleman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2020
<sup>68</sup>Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy ResultsChen Liu, Teli Liu, Zhongyi Zhang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 25, 2018
SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization FrameworkRudolf A Werner, Lilja B Solnes, Mehrbod S Javadi, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|February 12, 2021
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [<sup>111</sup> In]In-XYIMSR-01 for phase I regulatory approvalRavindra A De Silva, Michael A Gorin, Ronnie C Mease, et al.
Pageof 51

Showing results (401-410 of 504) with videos related to

Sort By:
Pageof 51
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
Radiology|July 19, 2022
<sup>18</sup>F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic ConfirmationGary A Ulaner, Beth Thomsen, Jeffrey Bassett, et al.
European Urology Focus|March 3, 2020
Cost-effectiveness Analysis of <sup>99m</sup>Tc-sestamibi SPECT/CT to Guide Management of Small Renal MassesZhuo T Su, Hiten D Patel, Mitchell M Huang, et al.
The Prostate|May 11, 2023
Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapyXinxing Du, Yanhao Dong, Jiazhou Liu, et al.
European Urology|September 21, 2015
Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe TumorsMichael A Gorin, Steven P Rowe, Alexander S Baras, et al.
Clinical Nuclear Medicine|March 22, 2023
Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and TherapyPhilipp E Hartrampf, Aleksander Kosmala, Sebastian E Serfling, et al.
The Prostate|July 31, 2019
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancerChanning J Paller, Danilo Piana, James R Eshleman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2020
<sup>68</sup>Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy ResultsChen Liu, Teli Liu, Zhongyi Zhang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 25, 2018
SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization FrameworkRudolf A Werner, Lilja B Solnes, Mehrbod S Javadi, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|February 12, 2021
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [<sup>111</sup> In]In-XYIMSR-01 for phase I regulatory approvalRavindra A De Silva, Michael A Gorin, Ronnie C Mease, et al.
Pageof 51